Results 61 to 70 of about 29,485 (291)

Engineering a novel IgG-like bispecific antibody against enterovirus A71

Biochemistry and Biophysics Reports, 2020
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection.
Hsiang-Ching Wang, Hui-Chen Hung, Peng-Nien Huang, Yu-An Kung, Sung-Nien Tseng, Yun-Ming Wang, Shin-Ru Shih, John Tsu-An Hsu   +7 more
doaj   +1 more source

Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of ‘Almost Natural’ Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection

Frontiers in Immunology, 2022
A subset of antibodies found in cattle comprises ultralong CDR-H3 regions of up to 70 amino acids. Interestingly, this type of immunoglobulin usually pairs with the single germline VL gene, V30 that is typically very conserved in sequence.
Daniel Klewinghaus, Lukas Pekar, Paul Arras, Simon Krah, Bernhard Valldorf, Harald Kolmar, Stefan Zielonka   +6 more
doaj   +1 more source

UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD‐L1 Transcription

Advanced Science, EarlyView.
UBE2O targets CDKL1 for the degradation to upregulate PD‐L1 expression and promotes resistance to radioimmunotherapy in lung cancer, supporting the potential of targeting UBE2O as a promising therapeutic strategy. ABSTRACT Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying
Huichan Xue, Xiaohua Jie, Zhiwei Liu, Ruoxin Fang, Shuo Wu, Xiaorong Dong, Shuangbing Xu   +6 more
wiley   +1 more source

Chemical generation of bispecific antibodies

, 2010
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability ...
Lingna Li, Richard A. Lerner, Nancy J. Levin, Abhijit Bhat, Gary Woodnutt, Joselyn Del Rosario, Robert E. Murphy, Michelle Parish, Curt W. Bradshaw, Venkata R. Doppalapudi, Dingguo Liu, Jie Huang, Bryan D. Oates, Jing-Yu Lai, Joel Desharnais, Marla J. Matin, Bin Liu, Michael J. Shields, Crystal Hagen, Ping Jin, Rodney W. Lappe, Zemeda Ainekulu   +21 more
core   +1 more source

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)

American Journal of Hematology, EarlyView.
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María‐Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld   +25 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function

, 2017
Asymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies.
Eric Escobar-Cabrera, Surjit Dixit, Joseph Schrag, Yves Durocher, Dixit, Surjit, Schrag, Joseph, Jason Baardsnes, Paula Lario, Escobar-Cabrera, Eric, Durocher, Yves, Lario, Paula, Baardsnes, Jason   +11 more
core   +1 more source

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

mAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero, Katharina B. Kroell, Lukas J. Grunewald, Anna-Lena M. Fischer, Jakob R. Riccabona, Klaus R. Liedl   +5 more
doaj   +1 more source